



October 17, 2016

Galectin Therapeutics to Webcast Corporate Presentation at the MicroCap Conference on October 25 in Philadelphia

NORCROSS, Ga., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the company's president, chief executive officer and chief medical officer, will present at The MicroCap Conference on Tuesday, October 25, 2016 at 8:30 a.m. ET. The conference is being held in Philadelphia, Pennsylvania at the Hotel Monaco.

The MicroCap Conference is an exclusive event for investors who specialize in small microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors. If you are a private investor or institutional investor interested in learning more about the conference, visit <http://microcapconf.com/conferences/philadelphia-2016/>.

A live webcast of the presentation may be accessed on the conference's website at <http://wsj.com/webcast/microcapconf2/galt>. The webcast and presentation will be archived for 90 days following the event on the company's website at www.galectintherapeutics.com.

About Galectin Therapeutics

Galectin Therapeutics is developing promising therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Contacts:

Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com.